This session will assess treatment options for patients with aspirin-exacerbated respiratory disease in light of the most recent data available on both aspirin therapy and new biologic therapy for asthma and nasal polyps.

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

  • Apply the latest data on biologics in asthma and nasal polyps to the patient population with AERD Identify patients with AERD who should be considered for aspirin desensitization
  • Define the benefits and risks of aspirin and biologic therapy for patients with AERD

 

Moderator Introduction
Elina Jerschow, MD FAAAAI
Albert Einstein College of Medicine

Aspirin Desensitization for AERD in 2020: An Update from the AERD Work Group
Whitney Stevens, MD, PhD
Northwestern University Feinberg School

Biomarker Response to Aspirin Therapy in AERD
Katherine  N. Cahill, MD
Vanderbilt University Medical Center

Treatment with Biologics for AERD in 2020
Tanya  M. Laidlaw, MD FAAAAI
Harvard Medical School

Please take a moment to click the link below and give us your feedback on this session:  

>>Evaluation